Naproxeno Sódico Kern Pharma (Naproxen Sodium)

Naproxen sodium, the active ingredient in Naproxeno Sódico Kern Pharma, is a nonsteroidal anti-inflammatory drug presented as an oral formulation for systemic use. It provides analgesic, anti‑inflammatory and antipyretic effects for adults experiencing pain, inflammation or fever.

GNH USA supplies Naproxeno Sódico Kern Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naproxen sodium acts on inflammatory pathways to relieve pain and reduce swelling in several musculoskeletal and febrile conditions. - Osteoarthritis: reduces joint pain and improves mobility. - Rheumatoid arthritis: diminishes inflammation and stiffness in affected joints. - Acute musculoskeletal pain: provides rapid analgesia for sprains, strains and back pain. - Dysmenorrhea: alleviates menstrual cramps and associated discomfort. - Fever: lowers elevated body temperature in febrile states.

Common Side Effects: - Gastrointestinal discomfort such as dyspepsia or nausea. - Headache. - Dizziness. - Mild skin rash.

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding. - Cardiovascular events including myocardial infarction or stroke. - Severe cutaneous reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, consider the following precautions: - Renal function: monitor in patients with impaired kidney function. - Cardiovascular risk: use cautiously in individuals with heart disease or hypertension. - Gastrointestinal history: avoid in patients with active peptic ulcer disease. - Concomitant anticoagulants: increased risk of bleeding. - Pregnancy and lactation: assess risk‑benefit ratio before use. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Naproxen sodium may interact with several drug classes. Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Selective COX‑2 inhibitors: additive renal toxicity. - Methotrexate: reduced clearance leading to toxicity. - Lithium: elevated serum lithium levels. Moderate Interactions (Monitor Closely): - ACE inhibitors: possible reduction in antihypertensive effect. - Diuretics: heightened risk of renal impairment. - SSRIs: increased potential for gastrointestinal bleeding.